Pegferon 180 mcg/0.5 ml (SC Injection)

Product Title and Categories

• Chronic Hepatitis C and B drug

Indications

• Treatment of adults with chronic hepatitis C virus infection
• Treatment of adult patients with chronic hepatitis B

Pharmacology

• Interferon proteins bound to polyethylene glycol (PEG) molecules
• Antiviral, antiproliferative, and immune-regulating activity

Dosage and Administration

• Recommended dose of 180 mcg once weekly for 48 weeks
• Subcutaneous administration on abdomen or thigh

Interaction

• Drugs metabolized by CYP1A2 monitoring
• Methadone toxicity monitoring
• Nucleoside analogues monitoring
• Zidovudine monitoring
• Azathioprine caution

Contraindications

• Hypersensitivity to any component of the product
• Autoimmune hepatitis
• Hepatic decompensation in cirrhotic patients
• Neonate or infants

Side Effects

• Depression and suicide
• Flu like symptoms
• Gastrointestinal effects
• Metabolic and Nutritional effects
• Musculoskeletal effects
• Neurological effects
• Psychiatric reactions
• Injection site reaction and skin problems
• Endocrine effects

Pregnancy and Lactation

• Category C for peginterferon alfa-2a monotherapy
• Category X for peginterferon and ribavirin combination in nursing mothers

Precautions and Warnings

• Patients who have failed alpha interferon treatment
• Liver or other organ transplant recipients
• Hepatitis B patients coinfected with HCV or HIV
• Hepatitis C patients coinfected with HBV or HIV

Use in Special Populations

• Dose modifications for adverse reactions
• Use caution in patients with hepatic or renal impairment

Overdose Effects

• Limited experiences of overdose
• No serious reactions attributed to overdose
• No specific antidote
• Dialysis ineffective

Therapeutic Class

• Hepatic viral infections (Hepatitis B)
• Hepatic viral infections (Hepatitis C)

Storage Conditions

• Store in refrigerator at 2-8° C
• Protect from light

Related Brands